NCT05378763 2026-02-18
PINNACLE
Spectrum Pharmaceuticals, Inc
Phase 3 Suspended
Clinical Trials
12 trialsNCT07376382 2026-02-02
SYNSTAR-02
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT06754644 2025-06-10
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05493501 2024-05-02
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
EQRx International, Inc.
Phase 3 Terminated
NCT05382728 2024-01-30
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
TYK Medicines, Inc
Phase 3 Recruiting
NCT00576225 2020-10-19
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
CTI BioPharma
Phase 3 Withdrawn
NCT02691299 2019-02-12
FALUCA
Hutchmed
Phase 3 Completed
NCT03656393 2018-09-04
RCTACSCNSCLC
Shenzhen People's Hospital
Phase 3 Unknown
NCT03269162 2017-09-14
Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection
Shanghai University of Traditional Chinese Medicine
Phase 3 Unknown
NCT00683514 2016-10-04
Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer
Pierre Fabre Medicament
Phase 3 Completed
NCT02140333 2015-02-12
Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 3 Unknown
NCT00298415 2013-10-25
Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Completed